WO2005085865A3 - Diagnostics and therapeutics for diseases associated with thyroid hormone receptor beta (thrb) - Google Patents

Diagnostics and therapeutics for diseases associated with thyroid hormone receptor beta (thrb) Download PDF

Info

Publication number
WO2005085865A3
WO2005085865A3 PCT/EP2005/001918 EP2005001918W WO2005085865A3 WO 2005085865 A3 WO2005085865 A3 WO 2005085865A3 EP 2005001918 W EP2005001918 W EP 2005001918W WO 2005085865 A3 WO2005085865 A3 WO 2005085865A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
thrb
therapeutics
diagnostics
diseases associated
Prior art date
Application number
PCT/EP2005/001918
Other languages
French (fr)
Other versions
WO2005085865A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2005085865A2 publication Critical patent/WO2005085865A2/en
Publication of WO2005085865A3 publication Critical patent/WO2005085865A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

The invention provides a human THRB which is associated with the cardiovascular diseases, infections, respiratory diseases, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, muscle-skeleton diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, infections, respiratory diseases, dermatological diseases, gastroenterological diseases, cancer, inflammation, metabolic diseases, hematological diseases, muscle-skeleton diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of THRB as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/001918 2004-03-09 2005-02-24 Diagnostics and therapeutics for diseases associated with thyroid hormone receptor beta (thrb) WO2005085865A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04005545.1 2004-03-09
EP04005545 2004-03-09

Publications (2)

Publication Number Publication Date
WO2005085865A2 WO2005085865A2 (en) 2005-09-15
WO2005085865A3 true WO2005085865A3 (en) 2006-01-26

Family

ID=34917169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/001918 WO2005085865A2 (en) 2004-03-09 2005-02-24 Diagnostics and therapeutics for diseases associated with thyroid hormone receptor beta (thrb)

Country Status (1)

Country Link
WO (1) WO2005085865A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115894665B (en) * 2022-07-14 2024-01-05 北京博奥森生物技术有限公司 THRB-CVD20 polypeptide fragment, polyclonal antibody prepared by using polypeptide fragment and application of polyclonal antibody

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996035785A2 (en) * 1995-05-11 1996-11-14 Karo Bio Ab Transgenic animals having a defective thyroid hormone receptor beta gene
US5883294A (en) * 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
WO2001060860A2 (en) * 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use
WO2002002488A2 (en) * 2000-06-30 2002-01-10 The Regents Of The University Of California Methods and compounds for modulating nuclear receptor coactivator binding
US6465258B1 (en) * 1999-01-07 2002-10-15 Tularik, Inc. FXR receptor-mediated modulation cholesterol metabolism
US20030166724A1 (en) * 2001-12-07 2003-09-04 Hangeland Jon J. Phenyl naphthol ligands for thyroid hormone receptor
WO2004007430A2 (en) * 2002-07-10 2004-01-22 Karo Bio Ab Benzamide or phenylacetamide derivatives useful as thyroid receptor ligands
WO2004045369A2 (en) * 2002-11-14 2004-06-03 Nura, Inc. Nuclear receptor-based diagnostic, therapeutic, and screening methods
WO2004060304A2 (en) * 2002-12-27 2004-07-22 Sagres Discovery, Inc. Novel compositions and methods in cancer
WO2004093799A2 (en) * 2003-04-18 2004-11-04 Bristol-Myers Squibb Company Thyroid receptor ligands

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996035785A2 (en) * 1995-05-11 1996-11-14 Karo Bio Ab Transgenic animals having a defective thyroid hormone receptor beta gene
US5883294A (en) * 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
US6465258B1 (en) * 1999-01-07 2002-10-15 Tularik, Inc. FXR receptor-mediated modulation cholesterol metabolism
WO2001060860A2 (en) * 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use
WO2002002488A2 (en) * 2000-06-30 2002-01-10 The Regents Of The University Of California Methods and compounds for modulating nuclear receptor coactivator binding
US20030166724A1 (en) * 2001-12-07 2003-09-04 Hangeland Jon J. Phenyl naphthol ligands for thyroid hormone receptor
WO2004007430A2 (en) * 2002-07-10 2004-01-22 Karo Bio Ab Benzamide or phenylacetamide derivatives useful as thyroid receptor ligands
WO2004045369A2 (en) * 2002-11-14 2004-06-03 Nura, Inc. Nuclear receptor-based diagnostic, therapeutic, and screening methods
WO2004060304A2 (en) * 2002-12-27 2004-07-22 Sagres Discovery, Inc. Novel compositions and methods in cancer
WO2004093799A2 (en) * 2003-04-18 2004-11-04 Bristol-Myers Squibb Company Thyroid receptor ligands

Also Published As

Publication number Publication date
WO2005085865A2 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
WO2006027147A3 (en) Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2006005469A3 (en) Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
WO2005103684A3 (en) Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1)
WO2005106491A3 (en) Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1)
WO2005076007A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y12 (p2y12)
WO2006021343A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine receptor 3a (5-ht3a)
WO2006010514A3 (en) Diagnostics and therapeutics for diseases associated with dual specificity mitogen-activated protein kinase kinase 5 (map2k5)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2005074969A3 (en) Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a1 (nr4a1)
WO2005085865A3 (en) Diagnostics and therapeutics for diseases associated with thyroid hormone receptor beta (thrb)
WO2005113786A3 (en) Diagnostics and therapeutics for diseases associated with chymase (cma1)
WO2005101001A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor, family c, group 5, member c (gprc5c)
WO2005031345A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor adipor2 (adipor2)
WO2005073729A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y11 (p2y11)
WO2006005470A3 (en) Diagnostics and therapeutics for diseases associated with mas related g-protein coupled receptor e (mrge)
WO2005101006A3 (en) Diagnostics and therapeutics for diseases associated with retinoid x receptor beta (rxrb)
WO2006013013A3 (en) Diagnostics and therapeutics for diseases associated with protective protein for beta-galactosidase (ppgb)
WO2005075983A3 (en) Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a3 (nr4a3)
WO2005075990A3 (en) Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a2 (nr4a2)
WO2005114209A3 (en) Diagnostics and therapeutics for diseases associated with g protein-dependent receptor kinase 2 (grk2)
WO2006013015A3 (en) Diagnostics and therapeutics for diseases associated with marapsin (mpn)
WO2005095631A3 (en) Diagnostics and therapeutics for diseases associated with mixed lineage kinase 4 alpha (mlk4 alpha)
WO2005101009A3 (en) Diagnostics and therapeutics for diseases associated with tachykinin receptor 2 (tacr2)
WO2005093426A3 (en) Diagnostics and therapeutics for diseases associated with retinoic acid receptor alpha (rara)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase